5,510 reports of this reaction
1.8% of all TREPROSTINIL reports
#10 most reported adverse reaction
INFUSION SITE PAIN is the #10 most commonly reported adverse reaction for TREPROSTINIL, manufactured by United Therapeutics Corporation. There are 5,510 FDA adverse event reports linking TREPROSTINIL to INFUSION SITE PAIN. This represents approximately 1.8% of all 313,927 adverse event reports for this drug.
TREPROSTINIL has an overall safety score of 85 out of 100. Patients taking TREPROSTINIL who experience infusion site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE PAIN is a less commonly reported adverse event for TREPROSTINIL, but still significant enough to appear in the safety profile.
In addition to infusion site pain, the following adverse reactions have been reported for TREPROSTINIL:
The following drugs have also been linked to infusion site pain in FDA adverse event reports:
INFUSION SITE PAIN has been reported as an adverse event in 5,510 FDA reports for TREPROSTINIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE PAIN accounts for approximately 1.8% of all adverse event reports for TREPROSTINIL, making it a notable side effect.
If you experience infusion site pain while taking TREPROSTINIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.